EUVIMEDEUVIMED entdecken
Crossref

Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A 2A Receptor Antagonists for Cancer Immunotherapy

Chenyu Zhu, Shuyin Ze, Ronghui Zhou, Xinyu Yang, Haojie Wang, Xiaolei Chai, Meimiao Fang, Mingyao Liu iD, Yonghui Wang iD, Weiqiang Lu iD, Qiong Xie

Journal of Medicinal Chemistry · 13.04.2023 · 66 (7) · 4734-4754

DOI: 10.1021/acs.jmedchem.2c01860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 23.03.2023. Verfasst von Chenyu Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China. Hauptthemen laut MEDLINE: Adenosine, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, ECNU Multifunctional Platform for Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies and clinical evidence have strongly supported the development of adenosine A2A receptor (A2AR) antagonists as novel approaches for cancer immunotherapy. By screening our in-house compound library, a pyridinone hit compound (1) with weak A2AR antagonistic activity was identified. Further structure-activity relationship studies revealed a series of pyridinone derivatives with strong potency. Compound 38 stood out with a potent A2AR antagonistic activity (IC50 = 29.0 nM), good mouse liver microsomal metabolic stability (t1/2 = 86.1 min), and excellent oral bioavailability (F = 86.1%). Of note, 38 effectively enhanced the activation and killing ability of T cells in vitro by down-regulation of immunosuppressive molecules (LAG-3 and TIM-3) and up-regulation of effector molecules (GZMB, IFNG, and IL-2). Moreover, 38 exhibited excellent in vivo antitumor activity with a tumor growth inhibition (TGI) of 56.0% in the MC38 tumor model via oral administration, demonstrating its potential as a novel A2AR antagonist candidate for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenosineNeoplasmsMiceAnimalsReceptor, Adenosine A2AAdenosine A2 Receptor AntagonistsImmunotherapy

Substanzen

AdenosineReceptor, Adenosine A2AAdenosine A2 Receptor Antagonists

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.
  • Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China.

ORCID-Profile: Mingyao Liu, Yonghui Wang, Weiqiang Lu

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • National Natural Science Foundation of China
  • ECNU Multifunctional Platform for Innovation
  • National Key Scientific Infrastructure for Translational Medicine

Zitieren

APA

Zhu, C., Ze, S., Zhou, R., Yang, X., Wang, H., Chai, X., Fang, M., Liu, M., Wang, Y., Lu, W., & Xie, Q. (2023). Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A 2A Receptor Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry, 66(7), 4734-4754. https://doi.org/10.1021/acs.jmedchem.2c01860

Vancouver

Zhu C, Ze S, Zhou R, Yang X, Wang H, Chai X, et al. Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A 2A Receptor Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry. 2023;66(7):4734-4754. doi:10.1021/acs.jmedchem.2c01860

BibTeX
@article{Zhu2023,
  author = {Zhu, Chenyu and Ze, Shuyin and Zhou, Ronghui and Yang, Xinyu and Wang, Haojie and Chai, Xiaolei and Fang, Meimiao and Liu, Mingyao and Wang, Yonghui and Lu, Weiqiang and Xie, Qiong},
  title = {Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A 2A Receptor Antagonists for Cancer Immunotherapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {7},
  pages = {4734--4754},
  doi = {10.1021/acs.jmedchem.2c01860}
}
Kostenlos starten →